Search research articles
Contact Us
Filters
Showing results (301-310 of 383) with videos related to
Page
of 39
Sort By:
Biorxiv : the Preprint Server for Biology
|
December 11, 2023
Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironment
Guoyu Yu, Paul G Corn, Celia Sze Ling Mak, et al.
Molecular Cancer Research : MCR
|
January 23, 2013
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis
Yu-Chen Lee, Jung-Kang Jin, Chien-Jui Cheng, et al.
The Lancet. Oncology
|
September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial
Paul G Corn, Elisabeth I Heath, Amado Zurita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
Christos N Papandreou, Danai D Daliani, Darrell Nix, et al.
Oncotarget
|
June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer
Theodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 30, 2012
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era
Sean E McGuire, Andrew K Lee, Jasmina Z Cerne, et al.
Developmental Cell
|
June 7, 2017
Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer
Song-Chang Lin, Yu-Chen Lee, Guoyu Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancer
Ana M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 5, 2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
Sumit K Subudhi, Ana Aparicio, Jianjun Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2015
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
Andreas Varkaris, Paul G Corn, Nila U Parikh, et al.
Page
of 39
Search research articles
Search
Showing results (301-310 of 383) with videos related to
Sort By:
Page
of 39
Biorxiv : the Preprint Server for Biology
|
December 11, 2023
Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironment
Guoyu Yu, Paul G Corn, Celia Sze Ling Mak, et al.
Molecular Cancer Research : MCR
|
January 23, 2013
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis
Yu-Chen Lee, Jung-Kang Jin, Chien-Jui Cheng, et al.
The Lancet. Oncology
|
September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial
Paul G Corn, Elisabeth I Heath, Amado Zurita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
Christos N Papandreou, Danai D Daliani, Darrell Nix, et al.
Oncotarget
|
June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer
Theodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 30, 2012
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era
Sean E McGuire, Andrew K Lee, Jasmina Z Cerne, et al.
Developmental Cell
|
June 7, 2017
Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer
Song-Chang Lin, Yu-Chen Lee, Guoyu Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancer
Ana M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 5, 2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
Sumit K Subudhi, Ana Aparicio, Jianjun Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2015
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
Andreas Varkaris, Paul G Corn, Nila U Parikh, et al.
Page
of 39